Search hospitals > North Dakota > Bismarck
Sanford Bismarck Medical Center
Claim this profileBismarck, North Dakota 58501
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
303 reported clinical trials
3 medical researchers
Summary
Sanford Bismarck Medical Center is a medical facility located in Bismarck, North Dakota. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Sanford Bismarck Medical Center is involved with conducting 303 clinical trials across 380 conditions. There are 3 research doctors associated with this hospital, such as Preston D. Steen, Daniel Almquist, and Maria Bell, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Preston D. SteenSanford Roger Maris Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
113 reported clinical trials
192 drugs studied
Daniel AlmquistSanford USD Medical Center - Sioux Falls2 years of reported clinical research
Expert in Breast Cancer
Expert in Lung Cancer
95 reported clinical trials
158 drugs studied
Maria Bell, MDSanford Cancer Center Oncology Clinic9 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
14 reported clinical trials
32 drugs studied
Clinical Trials running at Sanford Bismarck Medical Center
Lung Cancer
Breast Cancer
Esophageal cancer
Breast cancer
Ovarian Cancer
Bladder Cancer
Oropharyngeal Carcinoma
Kidney Cancer
Colorectal Cancer
Gastric cancer
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sanford Bismarck Medical Center?
Sanford Bismarck Medical Center is a medical facility located in Bismarck, North Dakota. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Sanford Bismarck Medical Center is involved with conducting 303 clinical trials across 380 conditions. There are 3 research doctors associated with this hospital, such as Preston D. Steen, Daniel Almquist, and Maria Bell, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.